We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.
Merck Receives Positive EU CHMP Opinion for CAPVAXIVEâ„¢ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.
The increase is driven by growth in oncology and cardiovascular, partially offset by declines in diabetes, vaccines, immunology, and virology. Merck's blockbuster cancer immunotherapy Keytruda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results